Hamill John P.'s Form 4 filing
Aprea Therapeutics, Inc. (APRE) · filed Feb 2, 2026
- Accession no.
- 0001104659-26-009203
- Filed
- Feb 2, 2026
- Trade date
- Jan 30, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $5.07K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hamill John P.CIK 0001716213 | Officer (SrVP/CFO/Prin Fin & Acct Ofcr) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Common Stock | PPurchaseAcquired | +5,700 | $0.89 | +$5,073 | 33,433 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Common Stock | PPurchaseAcquired | +5,700 | – | – | 5,700 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.